Nice | Prostate cancer

30th January 2014 by Louise Hudman

 

This updated guideline from Nice on prostate cancer has a couple of useful elements for us. The first is that they have standardised the protocol for ‘active surveillance’ and GPs are expected to be involved in the PSA monitoring aspect – so that is worth having a look at. The second aspect is about managing some of the side-effects of treatments.

Active surveillance

Patients with ‘low-risk’ cancers (ie those that are less likely to go on to cause further problems) and those with ‘intermediate-risk’ cancers who opt for it, can choose active surveillance. They are monitored with regular PSA, DRE (digital rectal exam) and biopsy. NICE encourages the use of GPs in the PSA monitoring aspect. They found that different centers around the country were doing very different things, so they have attempted to standardise what is done. This is based on expert consensus as trial evidence is lacking. ‘PSA kinetics’ means the speed of change (which we don’t need to worry about).

Side-effects of treatments

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I don’t normally do this, but just to say that I thought your article at the front of the latest NASGP magazine about clinical errors was really excellent. Great, and very thoughtful writing. NASGP member."

‘Great, and very thoughtful writing’

‘Great, and very thoughtful writing’

See the full list of features within our NASGP membership plans

Membership